Behary P et al demonstrated a hormone infusion therapy that could improve glycemia and reduce body weight in obese patients. The researchers utilised previously identified three specific hormones, found to be released in the bowel in higher levels after gastric bypass surgery. These hormones involving glucagon-like peptide-1 (GLP-1), oxyntomodulin and peptide termed as GOP was found to reduce appetite, cause weight loss and reduce high glucose levels. Twenty-six obese patients with prediabetes and those with diabetes were recruited in the study. Fifteen patients were randomly selected to receive the hormone treatment and 11 patients were given a saline infusion as a placebo over a four-week period. The team also recruited 21 patients who had undergone bariatric surgery (RYGB) and 22 patients who followed a very low-calorie diet (VLCD) to compare the results of GOP. The findings showed that patients on GOP treatment lost an average of 4.4 kg, compared with 2.5 kg for participants receiving a saline placebo. However, GOP showed a smaller weight loss compared with RYGB and VLCD which showed 10.3 kg and 8.3 kg respectively. GOP showed superior glucose tolerance and reduced variation in the blood glucose compared with RYGB and VLCD. Researchers show GOP infusion as an effective non-invasive treatment in improving glycemia and reducing body weight.
Source: Diabetes Care 2019 Aug; 42(8): 1446-1453.https://doi.org/10.2337/dc19-0449